F. Ratjen (Toronto, Canada), N. Regamey (Bern, Switzerland)
Longitudinal changes in lung function and the association with pulmonary structure and infection in infants with cystic fibrosis
N. Pillarisetti, B. Linnane, G. Hall, S. Brennan, S. Stick, P. Sly, C. Robertson, P. Robinson, S. Ranganathan (Melbourne, Perth, Australia)
|  |
Scond is an early and sensitive measure of airways dysfunction in CF
A. Horsley, K. Macleod, N. Bell, S. Cunningham, J. A. Innes (Edinburgh, United Kingdom)
|  |
Measuring trapped air by computed tomography (CT) in CF: in search of the optimal protocol
M. Loeve, M. Lequin, M. de Bruijne, I. Hartmann, W. Hop, H. Tiddens (Rotterdam, Netherlands; Copenhagen, Denmark)
|  |
Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate
C. Robroeks, R. Jobsis, R. Braeckers, H. Hendriks, E. Dompeling (Maastricht, Netherlands; Diepenbeek, Belgium)
| |
TLR-4 expression is reduced in cystic fibrosis bronchial epithelial cells
G. John, B. Rubin, D. Gruenert, M. Henke (Marburg, Germany; Winston-Salem, NC, San Francisco, CA, United States Of America)
| |
Acid and weakly acidic reflux, gastric aspiration and respiratory symptoms/function in children with cystic fibrosis
K. Blondeau, L. Dupont, V. Mertens, A. Pauwels, M. Proesmans, A. Malfroot, Y. Vandenplas, B. Hauser, D. Sifrim (Leuven, Brussels, Belgium)
| |
Supplementation with polyunsaturated fatty acids influence the inflammatory response and airway nitric oxide in patients with cystic fibrosis
C. Keen, A. C. Olin, S. Eriksson, A. Lindblad, A. Ekman, S. Basu, C. Beermann, B. Strandvik (Gothenburg, Uppsala, Sweden; Friedrichdorf, Germany)
| |
Use of a prostasin antagonist, AER 002, in obstructive lung disease: results of two phase 2 clinical trials in CF and COPD
M. Longphre, E. Burmeister Getz, W. M. Foster, M. King, A. Innes, O. Schmidt, R. Fuller (Berkeley, CA, Durham, NC, United States Of America; Edmonton, AB, Canada; Edinburgh, Scotland, Nottingham, England, United Kingdom)
| |